134 results on '"Sas, Theo"'
Search Results
102. Effect of Oxandrolone on Glucose Metabolism in Growth Hormone-Treated Girls with Turner Syndrome
- Author
-
Menke, Leonie A., primary, Sas, Theo C.J., additional, Stijnen, Theo, additional, Zandwijken, Gladys R.J., additional, de Muinck Keizer-Schrama, Sabine M.P.F., additional, Otten, Barto J., additional, and Wit, Jan M., additional
- Published
- 2010
- Full Text
- View/download PDF
103. Adult Height in Children with Growth Hormone Deficiency: A Randomized, Controlled, Growth Hormone Dose-Response Trial
- Author
-
Sas, Theo C.J., primary, de Ridder, Maria A.J., additional, Wit, Jan M., additional, Rotteveel, Joost, additional, Oostdijk, Wilma, additional, Reeser, H. Maarten, additional, Otten, Barto J., additional, and de Muinck Keizer-Schrama, Sabine M.P.F., additional
- Published
- 2010
- Full Text
- View/download PDF
104. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome
- Author
-
van Pareren, YK (Yvonne), Schrama, Sabine, Stijnen, T (Theo), Sas, Theo, Drop, Sten, van Pareren, YK (Yvonne), Schrama, Sabine, Stijnen, T (Theo), Sas, Theo, and Drop, Sten
- Published
- 2002
105. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial
- Author
-
Sas, Theo, Schrama, Sabine, Stijnen, T (Theo), Jansen, M, Otten, BJ, Hoorweg - Nijman, JJG, Vulsma, T, Massa, GG, Rouwé, CW, Reeser, HM, Gerver, WJ, Gosen, JJ, Rongen - Westerlaken, C, Drop, Sten, Sas, Theo, Schrama, Sabine, Stijnen, T (Theo), Jansen, M, Otten, BJ, Hoorweg - Nijman, JJG, Vulsma, T, Massa, GG, Rouwé, CW, Reeser, HM, Gerver, WJ, Gosen, JJ, Rongen - Westerlaken, C, and Drop, Sten
- Published
- 1999
106. Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial
- Author
-
Sas, Theo, Gerver, WJ, de Bruin, NC, Stijnen, T (Theo), Schrama, Sabine, Cole, TJ, van Teunenbroek, A (Arne), Drop, Sten, Sas, Theo, Gerver, WJ, de Bruin, NC, Stijnen, T (Theo), Schrama, Sabine, Cole, TJ, van Teunenbroek, A (Arne), and Drop, Sten
- Published
- 1999
107. Bone Mineral Density Assessed by Phalangeal Radiographic Absorptiometry Before and During Long-Term Growth Hormone Treatment in Girls with Turner's Syndrome Participating in a Randomized Dose-Response Study
- Author
-
Sas, Theo C J, primary, de Muinck Keizer-Schrama, Sabine M P F, additional, Stijnen, Theo, additional, van Teunenbroek, Arne, additional, van Leeuwen, Wibeke J, additional, Asarfi, Anjalie, additional, van Rijn, Rick R, additional, and Drop, Stenvert L, additional
- Published
- 2001
- Full Text
- View/download PDF
108. Turner’s Syndrome: A Paediatric Perspective
- Author
-
Sas, Theo C.J., primary and de Muinck Keizer-Schrama, Sabine M.P.F., additional
- Published
- 2001
- Full Text
- View/download PDF
109. Degree of methylation of ZAC1 (PLAGL1) is associated with prenatal and post-natal growth in healthy infants of the EDEN mother child cohort.
- Author
-
Azzi, Salah, Sas, Theo C. J., Koudou, Yves, Le Bouc, Yves, Souberbielle, Jean-Claude, Dargent-Molina, Patricia, Netchine, Irène, and Charles, Marie-Aline
- Published
- 2014
- Full Text
- View/download PDF
110. Final Height of Growth Hormone-Treated GH-Deficient Children and Girls with Turner’s Syndrome: The Dutch Experience
- Author
-
de Muinck Keizer-Schrama, Sabine, primary, van den Broeck, Jan, additional, Sas, Theo, additional, and Hokken-Koelega, Anita, additional
- Published
- 1999
- Full Text
- View/download PDF
111. Immunologic Effects of Background Prenatal and Postnatal Exposure to Dioxins and Polychlorinated Biphenyls in Dutch Infants
- Author
-
Weisglas-Kuperus, Nynke, primary, Sas, Theo C J, additional, Koopman-Esseboom, Corine, additional, Van Der Zwan, Cees W, additional, De Ridder, Maria A J, additional, Beishuizen, Auke, additional, Hooijkaas, Herbert, additional, and Sauer, Pieter J J, additional
- Published
- 1995
- Full Text
- View/download PDF
112. Effect of Oxandrolone on Glucose Metabolism in Growth Hormone-Treated Girls with Turner Syndrome.
- Author
-
Menke, Leonie A., Sas, Theo C.J., Stijnen, Theo, Zandwijken, Gladys R.J., de Muinck Keizer-Schrama, Sabine M.P.F., Otten, Barto J., and Wit, Jan M.
- Subjects
- *
DRUG efficacy , *TURNER'S syndrome , *HORMONE therapy , *ANDROGENS , *ESTROGEN replacement therapy , *CARBOHYDRATE metabolism , *THERAPEUTICS - Abstract
Background: The weak androgen oxandrolone (Ox) may increase height but may also affect glucose metabolism in girls with Turner syndrome (TS). Methods: In a randomized, placebo-controlled, double-blind study, we assessed the effect of Ox at a dosage of either 0.06 or 0.03 mg/kg/day on glucose metabolism in 133 growth hormone (GH)-treated girls with TS. Patients were treated with GH (1.33 mg/m2/day) from baseline, combined with placebo (Pl) or Ox from the age of 8, and estrogens from the age of 12. Oral glucose tolerance tests (OGTT) were performed, and HbA1c levels were measured before, during, and after discontinuing Ox/Pl therapy. Results: Insulin sensitivity, assessed by the whole-body insulin sensitivity index (WBISI) decreased during GH+Ox/Pl (p = 0.003) without significant differences between the dosage groups. Values returned to pre-treatment levels after discontinuing GH+Ox/Pl. On GH+Ox, fasting glucose was less frequently impaired (Ox 0.03, p = 0.001; Ox 0.06, p = 0.02) and HbA1c levels decreased more (p = 0.03 and p = 0.001, respectively) than on GH+Pl. Conclusions: We conclude that in GH-treated girls with TS, Ox at a dosage of 0.03 or 0.06 mg/kg/day does not significantly affect insulin sensitivity. Insulin sensitivity decreases during GH therapy, to return to a pre-treatment level after discontinuing therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
113. Degree of methylation of ZAC1(PLAGL1) is associated with prenatal and post-natal growth in healthy infants of the EDEN mother child cohort
- Author
-
Azzi, Salah, Sas, Theo CJ, Koudou, Yves, Le Bouc, Yves, Souberbielle, Jean-Claude, Dargent-Molina, Patricia, Netchine, Irène, and Charles, Marie-Aline
- Abstract
The ZAC1gene, mapped to the 6q24 region, is part of a network of co-regulated imprinted genes involved in the control of embryonic growth. Loss of methylation at the ZAC1differentially methylated region (DMR) is associated with transient neonatal diabetes mellitus, a developmental disorder involving growth retardation and diabetes in the first weeks of post-natal life. We assessed whether the degree of methylation of the ZAC1DMR in leukocytes DNA extracted from cord blood is associated with fetal, birth and post-natal anthropometric measures or with C-peptide concentrations in cord serum. We also searched for an influence of dietary intake and maternal parameters on ZAC1DMR methylation. We found positive correlations between the ZAC1DMR methylation index (MI) and estimated fetal weight (EFW) at 32 weeks of gestation, weight at birth and weight at one year of age (respectively, r = 0.15, 0.09, 0.14; Pvalues = 0.01, 0.15, 0.03). However, there were no significant correlations between the ZAC1DMR MI and cord blood C-peptide levels. Maternal intakes of alcohol and of vitamins B2 were positively correlated with ZAC1DMR methylation (respectively, r = 0.2 and 0.14; P= 0.004 and 0.04). The influence of ZAC1seems to start in the second half of pregnancy and continue at least until the first year of life. The maternal environment also appears to contribute to the regulation of DNA methylation.
- Published
- 2014
- Full Text
- View/download PDF
114. Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2023 Aarhus International Turner Syndrome Meeting.
- Author
-
Gravholt, Claus H, Andersen, Niels H, Christin-Maitre, Sophie, Davis, Shanlee M, Duijnhouwer, Anthonie, Gawlik, Aneta, Maciel-Guerra, Andrea T, Gutmark-Little, Iris, Fleischer, Kathrin, Hong, David, Klein, Karen O, Prakash, Siddharth K, Shankar, Roopa Kanakatti, Sandberg, David E, Sas, Theo C J, Skakkebæk, Anne, Stochholm, Kirstine, Velden, Janielle A van der, Group, The International Turner Syndrome Consensus, and Backeljauw, Philippe F
- Subjects
- *
TURNER'S syndrome , *PEDIATRIC endocrinology , *HUMAN reproduction , *ARABS , *HUMAN embryology - Abstract
Turner syndrome (TS) affects 50 per 100 000 females. TS affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, co-morbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and United States culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: (1) diagnosis and genetics, (2) growth, (3) puberty and estrogen treatment, (4) cardiovascular health, (5) transition, (6) fertility assessment, monitoring, and counselling, (7) health surveillance for comorbidities throughout the lifespan, and (8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
115. Availability, Usage, and Preferences of Estradiol and Progestogen Preparations for Puberty Induction from a Multicentral Perspective.
- Author
-
Gawlik-Starzyk, Aneta M., Więcek, Małgorzata, Matthews, Debbie, Kriström, Berit Öhman, van der Velden, Janielle A.E.M., Sas, Theo C.J., Wasniewska, Malgorzata, Verlinde, Siska, Brain, Caroline, Smyth, Arlene, and Donaldson, Malcolm David Cairns
- Abstract
Natural oestrogen administration as oral or transdermal 17β-estradiol is recommended for pubertal induction in girls with hypogonadism. However, suitable low-dose formulations are not consistently available globally. This questionnaire study aimed to identify the current availability of oestrogen and progesterone preparations worldwide.Introduction: Endorsed by the ESPE Turner Syndrome Working Group, the questionnaire targeted paediatric endocrinologists. Questions focused on accessibility of oral/transdermal 17β-estradiol and progestogen preparations. Responses were collected through a SurveyMonkey survey disseminated via ESPE channels, direct outreach, and conferences from June 2020 to December 2022.Methods: Participation included 229 healthcare professionals from 45 countries. Oral and transdermal 17β-estradiol in adult dosage was highly accessible (86.5% and 84.3%), with transdermal administration the preferred form (62.8%). Most commonly available estradiol preparations included 50 μg patches (32 countries) and 1 or 2 mg tablets (65.8% and 71.1% countries). However, 0.5 mg 17β-estradiol tablets were available in only 20% of respondents from 8 countries. Patches delivering 14 or 25 μg/day of 17β-estradiol were available in 3 and 20 countries, respectively. Oral progestogen had widespread availability (96.0%) and preference (87.0%), while transdermal usage was limited to 15.2% of respondents.Results: This study highlights global challenges in accessing suitable hormone preparations for female pubertal induction. In most countries, the lowest dose of the estradiol is 50 µg for patches and 2 mg for tablets. Appropriate low-dose 17β-estradiol tablets are much less available than low-dose patches. Our survey underscores the importance of adapting guidelines to local availability, and the need for improved accessibility to address these global disparities. [ABSTRACT FROM AUTHOR]Conclusion: - Published
- 2024
- Full Text
- View/download PDF
116. Does size matter? Hospital volume and resource use in paediatric diabetes care.
- Author
-
de Vries, Silvia A. G., Bak, Jessica C. G., Mul, Dick, Wouters, Michel W. J. M., Nieuwdorp, Max, Verheugt, Carianne L., and Sas, Theo C. J.
- Subjects
- *
MEDICAL care use , *HOSPITAL utilization , *MEDICAL quality control , *MEDICAL technology , *RESEARCH funding , *HOSPITAL care , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *PEDIATRICS , *LONGITUDINAL method , *ODDS ratio , *CONFIDENCE intervals , *DIABETES , *MEDICAL care costs , *SOCIAL classes - Abstract
Aims: Paediatric diabetes care has become increasingly specialised due to the multidisciplinary approach and technological developments. Guidelines recommend sufficient experience of treatment teams. This study evaluates associations between hospital volume and resource use and hospital expenditure in Dutch children with diabetes. Methods: Retrospective cohort study using hospital claims data of 5082 children treated across 44 Dutch hospitals (2019–2020). Hospitals were categorised into three categories; small (≥20–100 patients), medium (≥100–200 patients) and large (≥200 patients). All‐cause hospitalisations, consultations, technology and hospital expenditure were analysed and adjusted for age, sex, socio‐economic status (SES) and hospital of treatment. Results: Fewer hospitalisations were observed in large hospitals compared to small hospitals (OR 0.48; [95% CI 0.32–0.72]; p < 0.001). Median number of yearly paediatrician visits was 7 in large and 6 in small hospitals, the significance of which was attenuated in multilevel analysis (OR ≥7 consultations: 1.89; [95%CI 0.74–4.83]; p = 0.18). Technology use varies between individual hospitals, whereas pump usage and real‐time continuous glucose monitoring showed no significant differences between hospital volumes. Mean overall expenditure was highest in medium‐sized centres with €6434 per patient (IQR €2555–7955); the difference in diabetes care costs was not significant between hospital patient volumes. Conclusions: Care provision patterns vary by hospital patient volume. Large hospitals had the lowest hospitalisation rates. The use of diabetes technology was not different between hospital patient volumes. Medium‐sized hospitals showed the highest overall expenditure, but diabetes care costs were similar across hospital volumes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
117. 24 Immunological effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children: An exploratory study of health effects from ‘normal’ environmental exposure
- Author
-
Weisglas-Kuperus, Nynke, Patandin, Svati, Berbers, Guy A.M., Sas, Theo C.J., Mulder, Paul G.H., Sauer, Pieter J.J., and Hooijkaas, Herbert
- Published
- 2003
- Full Text
- View/download PDF
118. Transition readiness among adolescents with rare endocrine conditions
- Author
-
Alewijk, Lisette Van, Davidse, Kirsten, Pellikaan, Karlijn, Eck, Judith Van, Hokken-Koelega, A.c.s, Sas, Theo C.j., Hannema, Sabine, Van der Lely, Aart J, and de Graaff, Laura C.g.
- Abstract
Objective: Adolescents and young adults (AYA) with common endocrine disorders show a high dropout (up to 50%) after the transfer from paediatric to adult endocrinology. Little is known about transition readiness in rare endocrine conditions (rEC). This study aims to assess medical Self-Management Skills (SMS) among AYA with rEC in relation to age and gender, in order to understand dropout and increase transition readiness. Design: Cross-sectional study using web-based medical self-management questionnaires. Methods: Questionnaires consisting of 54 questions in seven domains were filled out by the adolescents before the first shared appointment with both paediatric and adult endocrinologist. Results: Fifty-seven patients (median age 17 y, 25/57 females) participated and generally scored well on most items. However, one out of seven did not know the name of their disorder, one sixth of the glucocorticoid users did not know that dose should be adapted in case of illness or surgery, over one fifth had never ordered their repeat prescriptions themselves and two thirds had never had a conversation alone with their doctor. Conclusions: Several SMS among patients with rEC are insufficient, with regard to medical knowledge, practical skills and communication. As SMS are only weakly related to non-modifiable factors like age and gender, we recommend focussing on other factors to increase transition readiness. The timing, amount and ‘mode’ of medical information should be individualised. Transition checklists should be used to detect shortcomings in practical skills and communication, which can subsequently be trained with the help of parents, caregivers and / or e-technology.
- Published
- 2019
- Full Text
- View/download PDF
119. Healthcare expenditure and technology use in pediatric diabetes care.
- Author
-
de Vries, Silvia A. G., Bak, Jessica C. G., Verheugt, Carianne L., Stangenberger, Vincent A., Mul, Dick, Wouters, Michel W. J. M., Nieuwdorp, Max, and Sas, Theo C. J.
- Subjects
- *
DIAGNOSIS of diabetes , *SCIENTIFIC observation , *BLOOD sugar monitoring , *AGE distribution , *HOSPITAL costs , *PEDIATRICS , *DIABETES , *RETROSPECTIVE studies , *MEDICAL care use , *COMPARATIVE studies , *DESCRIPTIVE statistics , *INSULIN pumps , *HOSPITAL care , *RESEARCH funding , *TECHNOLOGY - Abstract
Background: Diabetes mellitus is one of the most common chronic diseases in childhood. With more advanced care options including ever-evolving technology, allocation of resources becomes increasingly important to guarantee equal care for all. Therefore, we investigated healthcare resource utilization, hospital costs, and its determinants in Dutch children with diabetes. Methods: We conducted a retrospective, observational analysis with hospital claims data of 5,474 children with diabetes mellitus treated in 64 hospitals across the Netherlands between 2019–2020. Results: Total hospital costs were €33,002,652 per year, and most of these costs were diabetes-associated (€28,151,381; 85.3%). Mean annual diabetes costs were €5,143 per child, and treatment-related costs determined 61.8%. Diabetes technology significantly increased yearly diabetes costs compared to no technology: insulin pumps € 4,759 (28.7% of children), Real-Time Continuous Glucose Monitoring € 7,259 (2.1% of children), and the combination of these treatment modalities € 9,579 (27.3% of children). Technology use increased treatment costs significantly (5.9 – 15.3 times), but lower all-cause hospitalisation rates were observed. In all age groups, diabetes technology use influenced healthcare consumption, yet in adolescence usage decreased and consumption patterns changed. Conclusions: These findings suggest that contemporary hospital costs of children with diabetes of all ages are driven primarily by the treatment of diabetes, with technology use as an important additive factor. The expected rise in technology use in the near future underlines the importance of insight into resource use and cost-effectiveness studies to evaluate if improved outcomes balance out these short-term costs of modern technology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
120. Osteoporosis in children and adolescents: how to treat and monitor?
- Author
-
Ciancia, Silvia, Högler, Wolfgang, Sakkers, Ralph J. B., Appelman-Dijkstra, Natasha M., Boot, Annemieke M., Sas, Theo C. J., and Renes, Judith S.
- Subjects
- *
OSTEOPOROSIS , *BONE fractures , *CALLUS , *CHILD patients , *PEDIATRIC therapy , *INFLAMMATION - Abstract
Osteoporosis is a condition of increased bone fragility associated with fractures. Apart from primary genetic osteoporotic conditions, secondary osteoporosis in children is being increasingly recognized. As a result, there is growing interest in its prevention and treatment. Important goals of care are to prevent fractures, increase bone mass and trabecular and cortical thickness, reshape vertebral fractures, prevent (or correct) skeletal deformities, and improve mobility, independence, and quality of life. Secondary pediatric osteoporosis is often of multifactorial origin since affected children frequently have more than one acquired factor that is detrimental to bone health. Typical conditions causing osteoporosis are leukemias, progressive muscle or neurological disorders, as well as chronic inflammatory conditions and their treatment. Management of children with osteoporosis involves a multidisciplinary team involving pediatric experts from different subspecialties. With regard to prevention and early intervention, it is important to provide optimal management of any underlying systemic conditions including avoidance, or dose-reduction, of osteotoxic medications. Basic supporting life-style measures, such as appropriate nutrition, including adequate calcium intake and vitamin D, and physical activity are recommended, where possible. When pediatric treatment criteria for osteoporosis are met, antiresorptive drugs constitute the first pharmacological line treatment.
Conclusion: This clinical review focuses on the prevention, treatment, and follow-up of children with, or at risk of developing, osteoporosis and the transition from pediatric to adult care.What Is Known: • Osteoporosis and associated fractures can cause significant morbidity and reduce the quality of life. • The developing skeleton has huge potential for recovery and reshaping, thus early detection of fractures, assessment of recovery potential, and treatment of children with osteoporosis can prevent future fractures, deformities, and scoliosis, improve function and mobility, and reduce pain.What Is New: • Osteoporosis in children and adolescents requires a multidisciplinary approach with a thorough assessment of recovery potential, and indication for therapy should be personalized. • Although bisphosphonates still represent the drug most commonly used to increase bone mass, improve mobility, and reduce pain and recurrence of fractures, new agents are being developed and could be beneficial in children with specific conditions. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
121. Osteoporosis in children and adolescents: when to suspect and how to diagnose it.
- Author
-
Ciancia, Silvia, van Rijn, Rick R., Högler, Wolfgang, Appelman-Dijkstra, Natasha M., Boot, Annemieke M., Sas, Theo C. J., and Renes, Judith S.
- Abstract
Early recognition of osteoporosis in children and adolescents is important in order to establish an appropriate diagnosis of the underlying condition and to initiate treatment if necessary. In this review, we present the diagnostic work-up, and its pitfalls, of pediatric patients suspected of osteoporosis including a careful collection of the medical and personal history, a complete physical examination, biochemical data, molecular genetics, and imaging techniques. The most recent and relevant literature has been reviewed to offer a broad overview on the topic. Genetic and acquired pediatric bone disorders are relatively common and cause substantial morbidity. In recent years, there has been significant progress in the understanding of the genetic and molecular mechanistic basis of bone fragility and in the identification of acquired causes of osteoporosis in children. Specifically, drugs that can negatively impact bone health (e.g. steroids) and immobilization related to acute and chronic diseases (e.g. Duchenne muscular dystrophy) represent major risk factors for the development of secondary osteoporosis and therefore an indication to screen for bone mineral density and vertebral fractures. Long-term studies in children chronically treated with steroids have resulted in the development of systematic approaches to diagnose and manage pediatric osteoporosis. Conclusions: Osteoporosis in children requires consultation with and/or referral to a pediatric bone specialist. This is particularly relevant since children possess the unique ability for spontaneous and medication-assisted recovery, including reshaping of vertebral fractures. As such, pediatricians have an opportunity to improve bone mass accrual and musculoskeletal health in osteoporotic children. What is Known: • Both genetic and acquired pediatric disorders can compromise bone health and predispose to fractures early in life. • The identification of children at risk of osteoporosis is essential to make a timely diagnosis and start the treatment, if necessary. What is New: • Pediatricians have an opportunity to improve bone mass accrual and musculoskeletal health in osteoporotic children and children at risk of osteoporosis. • We offer an extensive but concise overview about the risk factors for osteoporosis and the diagnostic work-up (and its pitfalls) of pediatric patients suspected of osteoporosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
122. Mortality patterns in Dutch diabetes outpatients.
- Author
-
Bak JCG, de Vries SAG, Serné EH, Groenwold RHH, de Valk HW, Mul D, Sas TCJ, Bizino M, Nieuwdorp M, Kramer MHH, and Verheugt CL
- Subjects
- Humans, Netherlands epidemiology, Male, Female, Middle Aged, Adult, Aged, Cohort Studies, Registries, Young Adult, Risk Factors, Cardiovascular Diseases mortality, Cardiovascular Diseases epidemiology, Adolescent, Smoking epidemiology, Smoking adverse effects, Diabetes Mellitus, Type 2 mortality, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 1 mortality, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 epidemiology, Outpatients statistics & numerical data, COVID-19 mortality, COVID-19 epidemiology, COVID-19 complications, Cause of Death
- Abstract
Aim: Diabetes mellitus is a major cause of death. Outpatients with diabetes have more complications than patients in general practice; mortality patterns have only been studied in the total diabetes population. This study aims to assess mortality, causes, and predictors in outpatients with diabetes., Materials and Methods: A cohort study, included people with diabetes mellitus from the nationwide Dutch Paediatric and Adult Registry of Diabetes (DPARD) visiting diabetes outpatient clinics in 2016-2020. DPARD data were linked to Statistics Netherlands (CBS), comprising data on mortality, ethnicity and education. All-cause and cardiovascular mortality rates were estimated using Cox proportional hazard regression., Results: During a median follow-up of 3.1 years among 12 992 people with diabetes, mortality rates per 10 000 person-years were 67.7 in adult type 1 diabetes and 324.2 in type 2 diabetes. The major cause of non-cardiovascular death was malignancy. During the pandemic years of influenza (2018) and COVID (2020), mortality rates peaked. Age, smoking and an estimated glomerular filtration rate of <60 ml/min were associated with all-cause mortality. In type 2 diabetes, additional factors were male sex, body mass index <20 kg/m
2 , diabetes duration <1 year and hypertension., Conclusions: Mortality among Dutch outpatients with diabetes is high. Smoking and renal failure were associated with mortality in both types. Further focus on early detection and treatment of mortality-associated factors may improve clinical outcomes., (© 2024 John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
123. Cohort profile: the 'Biomarkers of heterogeneity in type 1 diabetes' study-a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands.
- Author
-
Aanstoot HJ, Varkevisser RDM, Mul D, Dekker P, Birnie E, Boesten LSM, Brugts MP, van Dijk PR, Duijvestijn PHLM, Dutta S, Fransman C, Gonera RK, Hoogenberg K, Kooy A, Latres E, Loves S, Nefs G, Sas T, Vollenbrock CE, Vosjan-Noeverman MJ, de Vries-Velraeds MMC, Veeze HJ, Wolffenbuttel BHR, and van der Klauw MM
- Subjects
- Humans, Female, Male, Netherlands, Adult, Prospective Studies, Middle Aged, Cross-Sectional Studies, Phenotype, Blood Glucose metabolism, Blood Glucose analysis, Young Adult, Disease Progression, C-Peptide blood, Aged, Adolescent, Diabetes Mellitus, Type 1 metabolism, Diabetes Mellitus, Type 1 blood, Glycated Hemoglobin analysis, Glycated Hemoglobin metabolism, Biomarkers blood
- Abstract
Purpose: The 'Biomarkers of heterogeneity in type 1 diabetes' study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D)., Participants: Data and samples were collected in two subsets. A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration from four Dutch Diabetes clinics between 2016 and 2021 (median age 32 years; median diabetes duration 12 years; 59% female; mean glycated haemoglobin (HbA1c) 61 mmol/mol (7.7%); 61% on insulin pump; 23% on continuous glucose monitoring (CGM)). Physical assessments were performed, blood and urine samples were collected, and participants completed questionnaires. A subgroup of participants underwent mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. A second cross-sectional cohort included participants with ≥35 years of T1D duration (currently n=160; median age 64 years; median diabetes duration 45 years; 45% female; mean HbA1c 58 mmol/mol (7.4%); 51% on insulin pump; 83% on CGM), recruited from five centres and measurements, samples and 5-year retrospective data were collected., Findings to Date: Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 min and 120 min showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Fasting residual C-peptide secretion is associated with a decreased risk of impaired awareness of hypoglycaemia., Future Plans: Research groups are invited to consider the use of these data and the sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNAs, metabolomics and gene expression data, combined with glucometrics, anthropometric and clinical data, and additional markers of residual beta-cell function., Trial Registration Number: NCT04977635., Competing Interests: Competing interests: Diabeter Netherlands is an independent clinic, which was acquired by Medtronic. The research presented here was independently performed and there is no conflict of interest., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
124. Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis.
- Author
-
Renes JS, Sas TCJ, Clement-de Boers A, Zwaveling-Soonawala N, Hannema SE, van der Velden JAEM, van der Kaay DCM, and Hokken-Koelega ACS
- Abstract
Introduction: Pycnodysostosis is an extremely rare skeletal dysplasia caused by cathepsin K deficiency. It is characterized by extreme short stature with adult height (AH) in males typically less than 150 cm and in females less than 130 cm. Our objective was to evaluate the effect and safety of growth hormone (GH) treatment in 6 patients with pycnodysostosis treated according to the Dutch national pycnodysostosis guideline., Case Presentation: Six subjects (4 boys, 2 girls) presented with pycnodysostosis, treated with GH 1.4 mg/m2/day (∼0.046 mg/kg/day) for ≥1 year. Median (IQR) age at start of GH was 10.4 years (5.7; 12.2) and median height 113.5 cm (93.3; 129.3) (-4.2 SDS [-4.8; -3.6]). All children were prepubertal at start of GH. After 1 year of GH, median height gain was 7.6 cm (6.5; 8.5) (0.3 SDS [-0.3; 0.7]). Three children are still treated with GH, and the other three subjects reached AH: 1 boy reached an AH of 157.0 cm (-3.8 SDS) after 6.3 years of GH, and 2 girls reached an AH of 138.5 cm (-5.2 SDS) after 4.8 years of GH and 148.0 cm (-3.6 SDS) after 6.4 years of GH, respectively. This last girl received additional GnRH analogue treatment. In all subjects, height SDS remained stable or improved during and after GH treatment. No serious adverse advents were found. Serum IGF-I remained below the +2 SDS., Conclusion: Our data suggest that GH may prevent the decline in height which can be observed in children with pycnodysostosis. Further research is needed to confirm this. Also, the effect of other growth-promoting strategies such as treatment with an additional GnRH analogue warrants further investigation., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
125. Socio-economic disparities in hospital care among Dutch patients with diabetes mellitus.
- Author
-
de Vries SAG, Sas TCJ, Bak JCG, Mul D, Nieuwdorp M, Wouters MWJM, and Verheugt CL
- Subjects
- Adult, Child, Humans, Blood Glucose Self-Monitoring, Blood Glucose, Insulin Infusion Systems, Insulin, Socioeconomic Factors, Hypoglycemic Agents adverse effects, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 1 therapy
- Abstract
Aim: Socio-economic status (SES) influences diabetes onset, progression and treatment. In this study, the associations between SES and use of hospital care were assessed, focusing on hospitalizations, technology and cardiovascular complications., Materials and Methods: This was an observational cohort study comprising 196 695 patients with diabetes (all types and ages) treated in 65 hospitals across the Netherlands from 2019 to 2020 using reimbursement data. Patients were stratified in low, middle, or high SES based on residential areas derived from four-digit zip codes., Results: Children and adults with low SES were hospitalized more often than patients with middle or high SES (children: 22%, 19% and 15%, respectively; p < .001, adults: 28%, 25% and 23%; p < .001). Patients with low SES used the least technology: no technology in 48% of children with low SES versus 40% with middle SES and 38% with high SES. In children, continuous subcutaneous insulin infusion (CSII) and real-time continuous glucose monitoring (rtCGM) use was higher in high SES {CSII: odds ratio (OR) 1.54 [95% confidence interval (CI) 1.35-1.76]; p < .001; rtCGM OR 1.39 [95% CI 1.20-1.61]; p < .001} and middle SES [CSII: OR 1.41 (95% CI 1.24-1.62); p < .001; rtCGM: OR 1.27 (95% CI 1.09-1.47); p = .002] compared with low SES. Macrovascular (OR 0.78 (95% CI 0.75-0.80); p < .001) and microvascular complications [OR 0.95 (95% CI 0.93-0.98); p < .001] occurred less in high than in low SES., Conclusions: Socio-economic disparities were observed in patients with diabetes treated in Dutch hospitals, where basic health care is covered. Patients with low SES were hospitalized more often, used less technology, and adults with high SES showed fewer cardiovascular complications. These inequities warrant attention to guarantee equal outcomes for all., (© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
126. Potency of quality indicators in Dutch and international diabetes registries.
- Author
-
Bak JCG, Serné EH, Wouters MWJM, de Valk HW, Mul D, Sas TCJ, Kramer MHH, Nieuwdorp M, and Verheugt CL
- Subjects
- Adult, Humans, Child, Glycated Hemoglobin, Blood Glucose Self-Monitoring, Blood Glucose, Registries, Quality Indicators, Health Care, Diabetes Mellitus epidemiology, Diabetes Mellitus therapy
- Abstract
Background: Diabetes mellitus forms a slow pandemic. Cardiovascular risk and quality of diabetes care are strongly associated. Quality indicators improve diabetes management and reduce mortality and costs. Various national diabetes registries render national quality indicators. We describe diabetes care indicators for Dutch children and adults with diabetes, and compare them with indicators established by registries worldwide., Methods: Indicator scores were derived from the Dutch Pediatric and Adult Registry of Diabetes Indicator sets of other national diabetes registries were collected and juxtaposed with global and continental initiatives for indicator sets., Results: This observational cohort study included 3738 patients representative of the Dutch diabetic outpatient population. The Dutch Pediatric and Adult Registry of Diabetes harbors ten quality indicators comprising treatment volumes, HbA1c control, foot examination, insulin pump therapy, and real-time continuous glucose monitoring. Worldwide, nine national registries record quality indicators, with great variety between registries. HbA1c control is recorded most frequently, and no indicator is reported among all registries., Conclusions: Wide variety among quality indicators recorded by national diabetes registries hinders international comparison and interpretation of quality of diabetes care. The potential of quality evaluation will be greatly enhanced when diabetes care indicators are aligned in an international standard set with variation across countries taken into consideration., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Max Nieuwdorp reports financial support was provided by Netherlands Organisation for Health Research and Development., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
127. Do sex differences in paediatric type 1 diabetes care exist? A systematic review.
- Author
-
de Vries SAG, Verheugt CL, Mul D, Nieuwdorp M, and Sas TCJ
- Subjects
- Child, Adult, Adolescent, Humans, Female, Male, Sex Characteristics, Quality of Life, Cross-Sectional Studies, Insulin, Diabetes Mellitus, Type 1
- Abstract
Aims/hypothesis: Sex differences are present in cardiovascular care and in outcomes among adults with type 1 diabetes mellitus, which typically commences in childhood. Whether sex influences care and outcomes in childhood is not known. This systematic review provides an overview of sex differences in children with type 1 diabetes, focusing on patient and disease characteristics, treatment, comorbidities and complications., Methods: Literature in MEDLINE up to 15 June 2021 was searched, using the terms diabetes mellitus, sex characteristics, sex distribution, children and/or adolescents. All primary outcome studies on children with type 1 diabetes that mentioned a sex difference in outcome were included, with the exception of qualitative studies, case reports or case series. Studies not pertaining to the regular clinical care process and on incidence or prevalence only were excluded. Articles reporting sex differences were identified and assessed on quality and risk of bias using Joanna Briggs Institute critical appraisal tools. Narrative synthesis and an adapted Harvest plot were used to summarise evidence by category., Results: A total of 8640 articles were identified, rendering 90 studies for review (n=643,217 individuals). Studies were of observational design and comprised cohort, cross-sectional and case-control studies. Most of the included studies showed a higher HbA
1c in young female children both at diagnosis (seven studies, n=22,089) and during treatment (20 out of 21 studies, n=144,613), as well as a steeper HbA1c increase over time. Many studies observed a higher BMI (all ages, ten studies, n=89,700; adolescence, seven studies, n=33,153), a higher prevalence of being overweight or obese, and a higher prevalence of dyslipidaemia among the female sex. Hypoglycaemia and partial remission occurred more often in male participants, and ketoacidosis (at diagnosis, eight studies, n=3561) and hospitalisation was more often seen in female participants. Most of the findings showed that female participants used pump therapy more frequently (six studies, n=211,324) and needed higher insulin doses than male participants. Several comorbidities, such as thyroid disease and coeliac disease, appeared to be more common in female participants. All studies reported lower quality of life in female participants (15 studies, n=8722). Because the aim of this study was to identify sex differences, studies with neutral outcomes or minor differences may have been under-targeted. The observational designs of the included studies also limit conclusions on the causality between sex and clinical outcomes., Conclusions/interpretation: Sex disparities were observed throughout diabetes care in children with type 1 diabetes. Several outcomes appear worse in young female children, especially during adolescence. Focus on the cause and treatment of these differences may provide opportunities for better outcomes., Registration: This systematic review is registered in PROSPERO (CRD42020213640)., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
128. [Neonatal herpes simplex infection].
- Author
-
van Ham-Borawitz VE, Stam ED, Welborn KM, and Sas TC
- Subjects
- Disease Progression, Female, Humans, Infant, Newborn, Pregnancy, Skin pathology, Antiviral Agents therapeutic use, Herpes Simplex diagnosis, Herpes Simplex drug therapy, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious drug therapy
- Abstract
Neonatal encephalitis caused by herpes simplex virus (HSV) is a familiar disease with a high mortality and morbidity rate. Isolated skin-eye-mouth infection is less familiar among professionals. In this article we present two neonates with an isolated skin lesion caused by an HSV infection. Of the neonates infected with HSV, 40-45% show isolated skin-eye-mouth disease. With correct treatment, the risk of spread to the central nervous system will decrease from 50-60% to 5-10%. Typical HSV skin lesions may present at a late stage of the disease or may be masked by a secondary bacterial infection. When a neonate presents with atypical skin lesions starting 7-12 days after the birth, immediate testing for HSV and immediate treatment are required, to decrease the risk of further progression of the disease.
- Published
- 2016
129. Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment.
- Author
-
Verver EJ, Freriks K, Sas TC, Huygen PL, Pennings RJ, Smeets DF, Hermus AR, Menke LA, Wit JM, Otten BJ, van Alfen-van der Velden JA, de Muinck Keizer-Schrama SM, Topsakal V, Admiraal RJ, Timmers HJ, and Kunst HP
- Subjects
- Adolescent, Adult, Anabolic Agents administration & dosage, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hearing, Hearing Loss genetics, Hearing Loss, Sensorineural genetics, Hearing Tests, Human Growth Hormone administration & dosage, Humans, Karyotype, Karyotyping, Oxandrolone administration & dosage, Turner Syndrome drug therapy, Turner Syndrome genetics, Young Adult, Anabolic Agents adverse effects, Hearing Loss epidemiology, Oxandrolone adverse effects, Turner Syndrome complications
- Abstract
Objective: To evaluate karyotype-specific ear and hearing problems in young-adult patients with Turner syndrome (TS) and assess the effects of previous treatment with oxandrolone (Ox)., Study Design: Double-blind follow-up study., Setting: University hospital., Patients: Sixty-five TS patients (mean age, 24.3 yr) previously treated with growth hormone combined with placebo, Ox 0.03 mg/kg per day, or Ox 0.06 mg/kg per day from the age of 8 years and estrogen from the age of 12 years., Intervention: Ear examination was performed according to standard clinical practice. Air- and bone conduction thresholds were measured in decibel hearing level., Main Outcome Measures: We compared patients with total monosomy of the short arm of the X chromosome (Xp), monosomy 45,X and isochromosome 46,X,i(Xq), with patients with a partial monosomy Xp, mosaicism or other structural X chromosomal anomalies. We assessed the effect of previous Ox treatment., Results: Sixty-six percent of the patients had a history of recurrent otitis media. We found hearing loss in 66% of the ears, including pure sensorineural hearing loss in 32%. Hearing thresholds in patients with a complete monosomy Xp were about 10 dB worse compared with those in patients with a partial monosomy Xp. Air- and bone conduction thresholds were not different between the placebo and Ox treatment groups., Conclusion: Young-adult TS individuals frequently have structural ear pathology, and many suffer from hearing loss. This indicates that careful follow-up to detect ear and hearing problems is necessary, especially for those with a monosomy 45,X or isochromosome 46,X,i(Xq). Ox does not seem to have an effect on hearing.
- Published
- 2014
- Full Text
- View/download PDF
130. [Clinical guideline 'Turner syndrome'].
- Author
-
van den Akker EL, van Alfen AA, Sas T, Kerstens M, Cools M, and Lambalk CB
- Subjects
- Adult, Aortic Dissection genetics, Aortic Dissection prevention & control, Aortic Aneurysm genetics, Aortic Aneurysm prevention & control, Belgium, Female, Humans, Infertility, Female etiology, Infertility, Female therapy, Karyotype, Netherlands, Practice Guidelines as Topic, Reproductive Techniques, Assisted, Turner Syndrome complications, Turner Syndrome genetics, Turner Syndrome diagnosis
- Abstract
Turner syndrome occurs in women who are missing one X chromosome. The most obvious symptoms are small stature and ovarian failure. Turner patients have an increased risk of a large number of disorders, and should therefore have lifelong medical supervision. Recent insights into patient management have been incorporated into the guidelines. Patients are increasingly involved in their own treatment. In patients with 45,X karyotype, Y-chromosomal material is actively sought in a larger number of cells and/or other tissues, using FISH. Pubertal induction therapy, if required, is initiated at an appropriate age. Egg donation or vitrification are new therapeutic options for fertility treatment. Monitoring for cardiac and vascular disease using cardiac ultrasound and MRI is performed more often, partly in connection with the risk of aortal dissection. The coordination of care of patients with Turner syndrome is concentrated in specialized centres in the Netherlands and Belgium.
- Published
- 2014
131. Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome.
- Author
-
Freriks K, Sas TC, Traas MA, Netea-Maier RT, den Heijer M, Hermus AR, Wit JM, van Alfen-van der Velden JA, Otten BJ, de Muinck Keizer-Schrama SM, Gotthardt M, Dejonckere PH, Zandwijken GR, Menke LA, and Timmers HJ
- Subjects
- Adult, Breast drug effects, Breast growth & development, Child, Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, Human Growth Hormone administration & dosage, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Virilism chemically induced, Body Height drug effects, Oxandrolone administration & dosage, Turner Syndrome drug therapy
- Abstract
Objective: Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg per day (Ox 0.03) significantly increased adult height gain, whereas Ox mg/kg per day (0.06) did not, at the cost of deceleration of breast development and mild virilization. The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment., Design and Methods: During the previous randomized controlled trial, 133 girls were treated with GH combined with placebo (Pl), Ox 0.03, or Ox 0.06 from 8 years of age and estrogen from 12 years. Sixty-eight women (Pl, n=23; Ox 0.03, n=27; and Ox 0.06, n=18) participated in the double-blind follow-up study (mean age, 24.0 years; mean time since stopping GH, 8.7 years; and mean time of Ox/Pl use, 4.9 years). We assessed height, body proportions, breast size, virilization, and body composition., Results: Height gain (final minus predicted adult height) was maintained at follow-up (Ox 0.03 10.2±4.9 cm, Ox 0.06 9.7±4.4 cm vs Pl 8.0±4.6 cm). Breast size, Tanner breast stage, and body composition were not different between groups. Ox-treated women reported more subjective virilization and had a lower voice frequency., Conclusion: Ox 0.03 mg/kg per day has a beneficial effect on adult height gain in TS patients. Despite previously reported deceleration of breast development during Ox 0.03 treatment, adult breast size is not affected. Mild virilization persists in only a small minority of patients. The long-term evaluation indicates that Ox 0.03 treatment is effective and safe.
- Published
- 2012
- Full Text
- View/download PDF
132. [Mauriac syndrome--a rare complication of type 1 diabetes mellitus].
- Author
-
Schmetz AV, Dekker-Maas MH, den Breejen MP, and Sas TC
- Subjects
- Adolescent, Blood Glucose metabolism, Child, Diabetes Mellitus, Type 1 drug therapy, Early Diagnosis, Female, Growth Disorders diagnosis, Hepatomegaly diagnosis, Humans, Male, Prognosis, Syndrome, Diabetes Mellitus, Type 1 complications, Growth Disorders etiology, Hepatomegaly etiology, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Patient Compliance
- Abstract
The treatment of children with type 1 diabetes mellitus has improved dramatically over the last few decades. The maintenance of acceptable metabolic control, nevertheless, remains challenging because the success of treatment is so dependent on patient compliance. Children with type 1 diabetes and poor metabolic control are at risk of developing Mauriac syndrome, a condition characterised by hepatomegaly, growth retardation and cushingoid features. A similar complication may occur in type-1 or type-2 adult diabetics; namely, glycogenic hepatopathy. We describe two children, a 12-year-old girl and a 16-year-old boy, who presented with classic symptoms of Mauriac syndrome. After metabolic control was achieved, reduction of hepatomegaly and the disappearance of cushingoid features were observed, proving the reversibility of the syndrome. Awareness that this syndrome still exists despite improved insulin therapy is crucial for earlier recognition and treatment.
- Published
- 2012
133. [Myalgia during warming-up in a 12-year-old boy].
- Author
-
Koenraads M, den Boer JA, Kerkhoff H, and Sas TC
- Subjects
- Child, Creatine Kinase blood, Glycogen Storage Disease Type V blood, Glycogen Storage Disease Type V complications, Humans, Male, Pain diagnosis, Pain etiology, Exercise physiology, Glycogen Phosphorylase, Muscle Form deficiency, Glycogen Storage Disease Type V diagnosis, Muscle, Skeletal enzymology
- Abstract
Introduction: McArdle disease is a hereditary myopathy caused by muscle phosphorylase deficiency. Patients experience painful muscle cramps after strenuous exercise; the condition is sometimes associated with rhabdomyolysis, myoglobinuria and resulting acute renal failure., Case Description: A 12-year-old boy visited the Paediatric and Neurology outpatients' departments with symptoms of leg myalgia, occurring during the warming-up phase of soccer practice, which disappeared after a short rest. Detailed history-taking revealed that he already experienced pain while walking during early childhood. An elevated serum creatine kinase concentration in combination with the typical presentation led to the presumptive diagnosis 'McArdle disease', which was confirmed by molecular genetic analysis., Conclusion: There is no effective gene therapy; a multidisciplinary approach by a neurologist, paediatrician, physiotherapist and nutritionist is advised.
- Published
- 2011
134. [Diagnostic image. A girl with cramp and tingling of the hands].
- Author
-
Harnisch E and Sas TC
- Subjects
- Child, Female, Hand pathology, Humans, Hypocalcemia blood, Hypocalcemia drug therapy, Pseudohypoparathyroidism blood, Pseudohypoparathyroidism drug therapy, Tetany blood, Tetany drug therapy, Calcium blood, Calcium therapeutic use, Hypocalcemia etiology, Pseudohypoparathyroidism complications, Pseudohypoparathyroidism diagnosis, Tetany etiology
- Abstract
An 8-year-old girl presented with cramp and tingling of the hands due to hypocalcaemia caused by pseudohypoparathyroidism.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.